Indivior Pharmaceuticals INDV Institutional Ownership

Ownership Summary

Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) is held by 284 institutional investors per 13F filings through March 2026.

• Their combined ownership stood at 97.4% of outstanding shares in March 2026, up from 6.8% in December 2025.
• Their total shares held in INDV increased 1333.42% quarter over quarter, and separately, investors owning Indivior Pharmaceuticals stayed flat from a year ago.
• During the quarter, 278 of these 284 funds increased positions in INDV, 3 reduced exposure, and 3 held steady.
• Institutional investors collectively held 120.8Mn shares in Indivior Pharmaceuticals as of March 2026, up by 112.37Mn shares quarter on quarter, and with no net change year over year.
• BlackRock, Inc. holds the largest position in INDV at 18.54Mn shares as of March 31, 2026, or 14.95% of shares outstanding.
• The most significant purchases of INDV for the quarter ending March 2026 came from BlackRock, Inc. (18.54Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (7.89Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.59Mn), State Street Corp (4.9Mn), Two Seas Capital LP (4.75Mn).
• The biggest sellers of Indivior Pharmaceuticals for the quarter ending March 2026 included Madison Avenue Partners, LP (1.97Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (120.3K), Bare Financial Services, Inc (17).
• According to Business Quant data, leading holders of INDV for March 2026 are BlackRock, Inc. (18.54Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (7.89Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.59Mn), State Street Corp (4.9Mn), Two Seas Capital LP (4.75Mn), MILLENNIUM MANAGEMENT LLC (4.6Mn), FULLER & THALER ASSET MANAGEMENT, INC. (4.53Mn), Madison Avenue Partners, LP (4.32Mn), CITADEL ADVISORS LLC (3.57Mn), Morgan Stanley (3.51Mn).